97 related articles for article (PubMed ID: 16830119)
21. Tc-99m methylene diphosphonate uptake by numerous phleboliths in the lower extremity detected incidentally during bone scintigraphy.
Sohn MH; Jeong YJ; Lim ST; Kim DW; Jeong HJ; Yim CY
Clin Nucl Med; 2010 Apr; 35(4):289-92. PubMed ID: 20305428
[No Abstract] [Full Text] [Related]
22. Production of 105Rh-EDTMP and its bone accumulation.
Ando A; Ando I; Tonami N; Kinuya S; Okamoto N; Sugimoto M; Fukuda N; Matsumoto S
Appl Radiat Isot; 2000 Feb; 52(2):211-5. PubMed ID: 10697730
[TBL] [Abstract][Full Text] [Related]
23. [Evaluation of 113mIn-DTPMP and 99mTc-MDP for bone scanning].
Yang JS
Zhonghua Fang She Xue Za Zhi; 1984 Feb; 18(1):58-62. PubMed ID: 6236062
[No Abstract] [Full Text] [Related]
24. Synthesis and biological evaluation of newly designed phosphonate based bone-seeking agent.
Srivastava P; Tiwari AK; Chadha N; Chuttani K; Mishra AK
Eur J Med Chem; 2013 Jul; 65():12-20. PubMed ID: 23688696
[TBL] [Abstract][Full Text] [Related]
25. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
Brenner W; Kampen WU; Kampen AM; Henze E
J Nucl Med; 2001 Feb; 42(2):230-6. PubMed ID: 11216521
[TBL] [Abstract][Full Text] [Related]
26. Predicting detectability in radioguided surgery: a study based on physical characterization of the probe and on tissue uptake ratios of 125I-, 153Sm- and 165Er-labelled radiopharmaceuticals.
Hassfjell SP; Skretting A; Bruland OS; Hoff P
Nucl Med Commun; 1998 Mar; 19(3):207-17. PubMed ID: 9625495
[TBL] [Abstract][Full Text] [Related]
27. Altered biodistribution of bone seeking agents in the presence of iron-overload.
Pérez-Lago Mdel S; De Vírgala MC; Siurana R; Ferrando MJ; Danús M; Izquierdo V; Pujol A
Clin Nucl Med; 2004 Mar; 29(3):214-6. PubMed ID: 15162998
[No Abstract] [Full Text] [Related]
28. Extra-skeletal uptake of bone agents.
Morton KA
J Nucl Med Technol; 1999 Mar; 27(1):51-3. PubMed ID: 10322578
[No Abstract] [Full Text] [Related]
29. Pre vivo, ex vivo and in vivo evaluations of [68Ga]-EDTMP.
Mitterhauser M; Toegel S; Wadsak W; Lanzenberger RR; Mien LK; Kuntner C; Wanek T; Eidherr H; Ettlinger DE; Viernstein H; Kluger R; Dudczak R; Kletter K
Nucl Med Biol; 2007 May; 34(4):391-7. PubMed ID: 17499728
[TBL] [Abstract][Full Text] [Related]
30. Uptake of technetium-99m MDP in primary amyloidosis with a review of the mechanisms of soft tissue localization of bone seeking radiopharmaceuticals.
Worsley DF; Lentle BC
J Nucl Med; 1993 Sep; 34(9):1612-5. PubMed ID: 8355083
[No Abstract] [Full Text] [Related]
31. [External therapy with radioactive urine: a pitfall during sceletal scintigraphy].
Scheidhauer K; Urbannek V
Nuklearmedizin; 1997 Dec; 36(8):292-4. PubMed ID: 17068881
[TBL] [Abstract][Full Text] [Related]
32. Radionuclide studies of bone metabolism: do bone uptake and bone plasma clearance provide equivalent measurements of bone turnover?
Blake GM; Siddique M; Frost ML; Moore AE; Fogelman I
Bone; 2011 Sep; 49(3):537-42. PubMed ID: 21689803
[TBL] [Abstract][Full Text] [Related]
33. The bench press mark revisited.
Meholic AJ; Hodge RG; Hartshorne MF
Clin Nucl Med; 1998 May; 23(5):325-6. PubMed ID: 9596163
[No Abstract] [Full Text] [Related]
34. Technetium-99m-labeled phosphonic acid analog of serine: bone uptake.
Surh Y; Spencer RP; Spitznagle LA; Hosain F; Lejczak B
J Nucl Med; 1986 Jun; 27(6):847-9. PubMed ID: 3712097
[TBL] [Abstract][Full Text] [Related]
35. Atypical Paget's disease with quantitative assessment of tracer kinetics.
Gnanasegaran G; Moore AE; Blake GM; Vijayanathan S; Clarke SE; Fogelman I
Clin Nucl Med; 2007 Oct; 32(10):765-9. PubMed ID: 17885354
[TBL] [Abstract][Full Text] [Related]
36. SPECT-CT for characterization of extraosseous uptake of 99mTc-methylene diphosphonate on bone scintigraphy.
Soundararajan R; Naswa N; Sharma P; Karunanithi S; Nazar AH; Das KJ; Bal C; Malhotra A; Kumar R
Diagn Interv Radiol; 2013; 19(5):405-10. PubMed ID: 23748034
[TBL] [Abstract][Full Text] [Related]
37. A report on the incidence of intestinal 99mTc-methylene diphosphonate uptake of bone scans and a review of the literature.
Ergün EL; Kiratli PO; Günay EC; Erbaş B
Nucl Med Commun; 2006 Nov; 27(11):877-85. PubMed ID: 17021428
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic and imaging evaluation of (99m)Tc-HBIDP as a potential bone imaging agent.
Qiu L; Lin J; Nan B; Lv G; Cheng W
Pak J Pharm Sci; 2015 May; 28(3):815-8. PubMed ID: 26004712
[TBL] [Abstract][Full Text] [Related]
39. Effect of asiaticoside on 99mTc-tetrofosmin and 99mTc-sestamibi uptake in MCF-7 cells.
Al-Saeedi FJ; Bitar M; Pariyani S
J Nucl Med Technol; 2011 Dec; 39(4):279-83. PubMed ID: 22080437
[TBL] [Abstract][Full Text] [Related]
40. The breast cancer cell line MCF7 as a model of 99mTc-SestaMIBI, 99mTc-tetrofosmin and 99mTc-Medronate incorporation.
Molteni SN; Seregni E; Botti C; Martinetti A; Ferrari L; Crippa F; Bombardieri E
Anticancer Res; 1999; 19(1A):255-9. PubMed ID: 10226551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
